Deciphera Pharmaceuticals is a biopharmaceutical company that develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. The company uses its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. Deciphera has a diverse pipeline of drug candidates, including three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 inhibits the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. The company is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Deciphera's switch control inhibitor, QINLOCK, is approved in multiple countries for the treatment of fourth-line GIST. Deciphera operates in the United States.